Acromegaly
Welcome,         Profile    Billing    Logout  
 24 Companies   9 Products   9 Products   6 Mechanisms of Action   49 Trials   4033 News 


«12...2627282930313233343536...6667»
  • ||||||||||  Retrospective data, Journal:  Revisiting growth hormone nadir cut-offs for remission in patients with acromegaly. (Pubmed Central) -  Apr 28, 2022   
    Results Female sex, as well as confirmed macroadenomas, were significantly overrepresented in group B. The 5-year rate of patients who achieved nadir GH <1.0 μg/L and age- and sex-matched normal IGF-1 was significantly higher in group A than that in group B. However, there was no significant difference between the two groups in metabolic parameters at 12 months post-operatively. Conclusion Different growth hormone nadir cut-offs were associated with different 5-year rates of patients who achieved nadir GH <1.0 μg/L and age- and sex-matched normal IGF-1, suggesting that a strict growth hormone nadir threshold of 0.4 μg/L correlates better with remission.
  • ||||||||||  Journal:  Sex difference in patients with controlled acromegaly - a multicenter survey. (Pubmed Central) -  Apr 28, 2022   
    In patients with acromegaly considered controlled, postmenopausal females exhibited higher GH levels than males despite comparable IGF-I levels, which also translated into impaired metabolic health and well-being. Our findings point to the relevance of including GH measurements in the assessment of disease control and suggest that disease-specific sex differences prevail after treatment.
  • ||||||||||  Journal:  Neurofibromatosis Type 1 Has a Wide Spectrum of Growth Hormone Excess. (Pubmed Central) -  Apr 24, 2022   
    Our findings show the variability in patterns of serial overnight GH secretion, somatotroph tumor or hyperplasia in some cases of NF1 and GH excess. Further studies are required to ascertain the link between NF1, GH excess and GPR101, which may aid in the characterization of the molecular underpinning of GH excess in NF1.
  • ||||||||||  Review, Journal:  Acromegaly: Clinical Care in Central and Eastern Europe, Israel, and Kazakhstan. (Pubmed Central) -  Apr 23, 2022   
    Further experience exchange will facilitate the identification of specific strategies that can be adapted in each country, and widespread participation in acromegaly registries will enable their evaluation. It is anticipated that this approach will support the optimization of acromegaly patient care across this region.
  • ||||||||||  Journal:  Acromegaly and cardiovascular outcomes: a cohort study. (Pubmed Central) -  Apr 19, 2022   
    Patients with acromegaly were at higher risk for atrial fibrillation, congestive heart failure, and all-cause death. The risk of atrial fibrillation had a time-dependent association with acromegaly.
  • ||||||||||  How to Manage Nelson Syndrome (In Person and Livestreamed A311-A312) -  Apr 18, 2022 - Abstract #ENDO2022ENDO_202;    
    The risk of atrial fibrillation had a time-dependent association with acromegaly. This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy
  • ||||||||||  How to Manage and Monitor Cushing's After Radio Therapy (In Person and Livestreamed A311-A312) -  Apr 18, 2022 - Abstract #ENDO2022ENDO_201;    
    This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy
  • ||||||||||  Discrepancies in Growth Hormone and IGF1 In Acromegaly (In Person and Livestreamed A311-A312) -  Apr 18, 2022 - Abstract #ENDO2022ENDO_200;    
    This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy
  • ||||||||||  Journal:  Direct effects of octreotide on osteoblast cell proliferation and function. (Pubmed Central) -  Apr 13, 2022   
    This session aims to cover challenging areas in the clinical practice with a special focus on acromegaly and Cushing's disease.Learning Objective 1:To gain insight on the discordant biochemical results in acromegaly and their significance Learning Objective 2:To understand management options and their outcomes in Nelson's syndrome Learning Objective 3:To acquire knowledge on the follow-up and management of patients with Cushing's who had pituitary radiotherapy This study provides the first evidence of the direct action of OCT on osteoblasts which may have clinically relevant implications for the management of skeletal health in subjects with acromegaly and metastatic NETs.
  • ||||||||||  Journal:  Optimal timing of blood samplings to detect GH inhibition during oral glucose tolerance test. (Pubmed Central) -  Apr 13, 2022   
    A subset of 4 time-points (60' - 90' - 120' - 150') was identified as the most relevant to detect GH suppression at OGTT, with a perfect classification of 100% of subjects. This supports the possibility to restrict the blood samplings to these time-points when assessing disease cure, with possible advantages in terms of saving time and lowering costs.
  • ||||||||||  Retrospective data, Journal:  Extraocular Muscle Enlargement in Growth Hormone-Secreting Pituitary Adenomas. (Pubmed Central) -  Apr 13, 2022   
    We describe a high prevalence of extraocular muscle enlargement in patients with growth hormone-secreting pituitary adenomas. Additionally, we note that the size of extraocular muscles decreased with associated improvement in the biochemical control of acromegaly.
  • ||||||||||  Review, Journal:  Anesthesia for Pituitary Surgery. (Pubmed Central) -  Apr 9, 2022   
    The anesthesiologist is able to assist the surgeons by keeping the patient motionless and lowering the blood pressure to minimize surgical bleeding. Postoperative nausea and vomiting are also of greater importance than usual, as the Valsalva movements associated with retching could cause bleeding and disruption of the surgical site.
  • ||||||||||  Journal:  Clinical Biology of the Pituitary Adenoma. (Pubmed Central) -  Apr 9, 2022   
    For most clinically apparent adenomas, multimodal therapy controlling hormone secretion and adenoma growth lead to improved quality of life and normalized mortality. The clinical biology of pituitary adenomas and particularly their benign nature stands in marked contrast to other tumors of the endocrine system such as thyroid and neuroendocrine tumors.
  • ||||||||||  Review, Journal:  Risk Factors for Colorectal Polyps and Cancer. (Pubmed Central) -  Apr 8, 2022   
    A history of abdominopelvic radiation, acromegaly, hereditary hemochromatosis, or prior ureterosigmoidostomy also increases CRC risk. Understanding these risk factors allows for targeted screening of high-risk groups to reduce CRC incidence.
  • ||||||||||  Journal:  Cardiovascular complications associated with acromegaly. A state-of-the-art (Pubmed Central) -  Apr 8, 2022   
    After the literature overview related to the pathophysiology, clinical manifestations, diagnosis and treatment of cardiovascular involvement, we found that from a cardiovascular point of view, patients with acromegaly can range from an asymptomatic state to severe cardiac dysfunction, being the biochemical markers and imaging studies diagnostic tools that allow assessment the degree of cardiovascular disease in order to provide individualized treatment. The normalization of growth hormone and insulin-like growth factor 1 levels improves cardiovascular parameters, and therefore its prognosis.
  • ||||||||||  Clinical, Journal:  Differences in somatostatin receptor subtype expression in patients with acromegaly: new directions for targeted therapy? (Pubmed Central) -  Apr 7, 2022   
    The present study indicates that there is no significant relationship between the expression rates of receptor subtypes and the parameters we analyzed. However, our study revealed that smaller adenomas have a lower baseline GH level (p = 0.015), IHC with monoclonal antibodies appears to be a suitable method to determine the expression rates of SSTR2a and 5 at protein levels, as it is not possible to draw conclusions regarding receptor subtypes solely on the basis of the parameters analyzed.
  • ||||||||||  Review, Journal:  Acromegaly: Medical and Surgical Considerations. (Pubmed Central) -  Apr 6, 2022   
    Transsphenoidal resection is the primary therapy for individuals with acromegaly, even in the cases where gross total resection is not possible because of parasellar extension and cavernous sinus involvement. For recurrent or persistent disease after resection, systemic medications and stereotactic radiosurgery are used.
  • ||||||||||  Journal:  Observation of Clinicopathologic Features of Pituitary Adenoma With Neuronal Differentiation. (Pubmed Central) -  Apr 5, 2022   
    Our results suggest that PIT1-positive pituitary adenomas may have neural differentiation potential, which may not be unusual. This indication supports the possibility that the neuronal transdifferentiation of adenomatous cells is a possible mechanism, and the underlying mechanism requires further elucidation.
  • ||||||||||  Review, Journal:  Endocrine Disorders with Parathyroid Hormone-Independent Hypercalcemia. (Pubmed Central) -  Apr 1, 2022   
    These are differential diagnoses when assessing the hypercalcemic patient for whom common causes have been excluded. Further investigation is needed regarding hypothyroidism; acromegaly, hyperprolactinemia, gonadal dysfunction, and diabetes are not associated with hyperthyroidism.
  • ||||||||||  Clinical, Journal:  Reversible insulin resistance in muscle and fat unrelated to the metabolic syndrome in patients with acromegaly. (Pubmed Central) -  Apr 1, 2022   
    Further investigation is needed regarding hypothyroidism; acromegaly, hyperprolactinemia, gonadal dysfunction, and diabetes are not associated with hyperthyroidism. In conclusion, the study support that uncontrolled lipolysis is a major feature of insulin resistance in active acromegaly, and is characterized by upregulation of PTEN and suppression of insulin signalling in both muscle and fat.